Biophytis Financial Statements From 2010 to 2025
| BPTSDelisted Stock | USD 7.03 0.00 0.00% |
Check Biophytis financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biophytis' main balance sheet or income statement drivers, such as , as well as many indicators such as . Biophytis financial statements analysis is a perfect complement when working with Biophytis Valuation or Volatility modules.
Biophytis |
Biophytis Company Shares Outstanding Analysis
Biophytis' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Biophytis Shares Outstanding | 286.5 K |
Most of Biophytis' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biophytis is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
CompetitionBased on the latest financial disclosure, Biophytis has 286.5 K of shares currently outstending. This is 99.84% lower than that of the Biotechnology sector and 99.73% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 99.95% higher than that of the company.
Biophytis Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biophytis's current stock value. Our valuation model uses many indicators to compare Biophytis value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biophytis competition to find correlations between indicators driving Biophytis's intrinsic value. More Info.Biophytis is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Biophytis by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.About Biophytis Financial Statements
Biophytis shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Biophytis investors may analyze each financial statement separately, they are all interrelated. The changes in Biophytis' assets and liabilities, for example, are also reflected in the revenues and expenses on on Biophytis' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. The company was incorporated in 2006 and is headquartered in Paris, France. Biophytis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Biophytis Stock
If you are still planning to invest in Biophytis check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biophytis' history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |